Searching…
Feb 22, 2021 · Methods: This was a pre-specified, stratified, subgroup analysis of the STEMI cohort from the TICO (Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for ...
Oct 15, 2020 · TICO研究为 急性冠脉综合征（ACS）患者支架植入后采取替格瑞洛单药治疗提供了强有力的证据，此次公布于2020年美国经导管心血管治疗学术会议（TCT 2020）的TICO-STEMI为上述研究的子研究，进一步评估了DES治疗STEMI患者行3个月 DAPT（阿司匹林+替格瑞洛）后单用替格 ...
PCI术后1-3个月：进入“选择期”。 TARGET-FIRST、TICO、T-PASS一致证明，在这个时间段转为P2Y12抑制剂单药治疗是安全有效的，尤其适用于低危、完全血运重建、出血风险高的患者。 PCI术后3-12个月： 对于高缺血风险患者，继续双抗；对于已转为单药治疗者，维持单药。
Oct 12, 2020 · TICO trial ... − A prospective, randomized, multi-center trial conducted at 38 centers in South Korea − All types of ACS (UA, 30.3%; NSTEMI, 33.6%; and STEMI, 36.1%) were enrolled. − According to the pr...
Oct 22, 2020 · 2020年10月15日，在2020美国经导管心血管治疗学术会议上（TCT 2020）公布了TICO研究的亚组分析结果，探讨了在药物洗脱支架患者中应用替格瑞洛单药治疗的安全性与可行性，为替格瑞洛治疗S…
Apr 14, 2020 · 此研究结果无疑为替格瑞洛单药治疗方案新增了强有力的证据。 “我们的发现表明，对于接受支架治疗的ACS患者，替格瑞洛单药治疗可能是降低出血风险而不增加动脉阻塞引起不良事件风险的最佳策略。 ” Yangsoo Jang教授表示。
In the TICOtrial, among ACS patients treated with Orsiro®, ticagrelor monotherapy after 3-m DAPT showed significantly lower rates of Net Adverse Clinical Events (NACE) compared to 12-m conventional DAPT therapy (3.9% ...
Thus, the aims of the present post-hoc analysis of the TICOtrial were: 1) to apply HBR by ARC-HBR criteria and PRECISE-DAPT score for clinical outcomes; and 2) to investigate the impact of ticagrelor monotherapy after...
Oct 24, 2020 · 研究设计 TICO研究是一项前瞻性、开放标签、多中心的随机对照临床试验。 共纳入3056名19～80岁的ACS患者，接受生物可吸收聚合物＋西罗莫司药物洗脱支架植入术。
Despite of the superior effect of ticagrelor monotherapy in the main TICO trial, the lower-than-expected rate of adverse events could have limited the power of our analyses.
